FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3137016834> ?p ?o ?g. }

• W3137016834 abstract "In the INBUILD trial in patients with chronic fibrosing interstitial lung diseases (ILDs) and a progressive phenotype, nintedanib reduced the rate of ILD progression with adverse events that were manageable for most patients. We investigated the potential impact of immunomodulatory therapies on the efficacy and safety of nintedanib.Subjects with fibrosing ILDs other than idiopathic pulmonary fibrosis, who had shown progression of ILD within the prior 24 months despite management in clinical practice, were randomized to receive nintedanib or placebo. Certain immunomodulatory therapies were restricted for the first 6 months. We analyzed post-hoc the rate of decline in forced vital capacity (FVC) over 52 weeks in subgroups by glucocorticoid use at baseline and in analyses excluding subjects or FVC measurements taken after initiation of restricted immunomodulatory or antifibrotic therapies.Of 663 subjects, 361 (54.4%) were taking glucocorticoids at baseline (353 at a dose of ≤ 20 mg/day). In the placebo group, the adjusted rate of decline in FVC (mL/year) over 52 weeks was numerically greater in subjects taking than not taking glucocorticoids at baseline (- 206.4 [SE 20.2] vs - 165.8 [21.9]). The difference between the nintedanib and placebo groups was 133.3 (95% CI 76.6, 190.0) mL/year in subjects taking glucocorticoids at baseline and 76.1 (15.0, 137.2) mL/year in subjects who were not (interaction P = 0.18). The effect of nintedanib on reducing the rate of FVC decline in analyses excluding subjects or measurements taken after initiation of restricted immunomodulatory or antifibrotic therapies was similar to the primary analysis. The adverse event profile of nintedanib was similar between subjects who did and did not use prohibited or restricted therapies at baseline or during treatment with trial drug.In patients with progressive fibrosing ILDs, the effect of nintedanib on reducing FVC decline was not influenced by the use of immunomodulatory therapies. Nintedanib can be used in combination with immunomodulatory therapies in patients with progressive fibrosing ILDs. Trial registration ClinicalTrials.gov, NCT02999178. Registered 21 December 2016, https://clinicaltrials.gov/ct2/show/NCT02999178." @default.
• W3137016834 created "2021-03-29" @default.
• W3137016834 creator A5006679909 @default.
• W3137016834 creator A5007461514 @default.
• W3137016834 creator A5009383674 @default.
• W3137016834 creator A5014703126 @default.
• W3137016834 creator A5019441565 @default.
• W3137016834 creator A5025873566 @default.
• W3137016834 creator A5034439885 @default.
• W3137016834 creator A5038846995 @default.
• W3137016834 creator A5055570107 @default.
• W3137016834 creator A5065730561 @default.
• W3137016834 creator A5078029953 @default.
• W3137016834 creator A5091576695 @default.
• W3137016834 date "2021-03-16" @default.
• W3137016834 modified "2023-10-05" @default.
• W3137016834 title "Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases" @default.
• W3137016834 cites W1710057076 @default.
• W3137016834 cites W2098305693 @default.
• W3137016834 cites W2138871107 @default.
• W3137016834 cites W2587338330 @default.
• W3137016834 cites W2789284875 @default.
• W3137016834 cites W2804065941 @default.
• W3137016834 cites W2889197569 @default.
• W3137016834 cites W2906077632 @default.
• W3137016834 cites W2906351508 @default.
• W3137016834 cites W2922513760 @default.
• W3137016834 cites W2923176155 @default.
• W3137016834 cites W2945521814 @default.
• W3137016834 cites W2964216559 @default.
• W3137016834 cites W2974960379 @default.
• W3137016834 cites W2999937905 @default.
• W3137016834 cites W3010166382 @default.
• W3137016834 cites W3013021754 @default.
• W3137016834 doi "https://doi.org/10.1186/s12931-021-01668-1" @default.
• W3137016834 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7962343" @default.
• W3137016834 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33726766" @default.
• W3137016834 hasPublicationYear "2021" @default.
• W3137016834 type Work @default.
• W3137016834 sameAs 3137016834 @default.
• W3137016834 citedByCount "29" @default.
• W3137016834 countsByYear W31370168342021 @default.
• W3137016834 countsByYear W31370168342022 @default.
• W3137016834 countsByYear W31370168342023 @default.
• W3137016834 crossrefType "journal-article" @default.
• W3137016834 hasAuthorship W3137016834A5006679909 @default.
• W3137016834 hasAuthorship W3137016834A5007461514 @default.
• W3137016834 hasAuthorship W3137016834A5009383674 @default.
• W3137016834 hasAuthorship W3137016834A5014703126 @default.
• W3137016834 hasAuthorship W3137016834A5019441565 @default.
• W3137016834 hasAuthorship W3137016834A5025873566 @default.
• W3137016834 hasAuthorship W3137016834A5034439885 @default.
• W3137016834 hasAuthorship W3137016834A5038846995 @default.
• W3137016834 hasAuthorship W3137016834A5055570107 @default.
• W3137016834 hasAuthorship W3137016834A5065730561 @default.
• W3137016834 hasAuthorship W3137016834A5078029953 @default.
• W3137016834 hasAuthorship W3137016834A5091576695 @default.
• W3137016834 hasBestOaLocation W31370168341 @default.
• W3137016834 hasConcept C126322002 @default.
• W3137016834 hasConcept C142724271 @default.
• W3137016834 hasConcept C165637977 @default.
• W3137016834 hasConcept C197934379 @default.
• W3137016834 hasConcept C204787440 @default.
• W3137016834 hasConcept C27081682 @default.
• W3137016834 hasConcept C2777543607 @default.
• W3137016834 hasConcept C2777714996 @default.
• W3137016834 hasConcept C2778341716 @default.
• W3137016834 hasConcept C2780171596 @default.
• W3137016834 hasConcept C2780559512 @default.
• W3137016834 hasConcept C2781244666 @default.
• W3137016834 hasConcept C3018587741 @default.
• W3137016834 hasConcept C55520419 @default.
• W3137016834 hasConcept C71924100 @default.
• W3137016834 hasConcept C90924648 @default.
• W3137016834 hasConceptScore W3137016834C126322002 @default.
• W3137016834 hasConceptScore W3137016834C142724271 @default.
• W3137016834 hasConceptScore W3137016834C165637977 @default.
• W3137016834 hasConceptScore W3137016834C197934379 @default.
• W3137016834 hasConceptScore W3137016834C204787440 @default.
• W3137016834 hasConceptScore W3137016834C27081682 @default.
• W3137016834 hasConceptScore W3137016834C2777543607 @default.
• W3137016834 hasConceptScore W3137016834C2777714996 @default.
• W3137016834 hasConceptScore W3137016834C2778341716 @default.
• W3137016834 hasConceptScore W3137016834C2780171596 @default.
• W3137016834 hasConceptScore W3137016834C2780559512 @default.
• W3137016834 hasConceptScore W3137016834C2781244666 @default.
• W3137016834 hasConceptScore W3137016834C3018587741 @default.
• W3137016834 hasConceptScore W3137016834C55520419 @default.
• W3137016834 hasConceptScore W3137016834C71924100 @default.
• W3137016834 hasConceptScore W3137016834C90924648 @default.
• W3137016834 hasFunder F4320310441 @default.
• W3137016834 hasIssue "1" @default.
• W3137016834 hasLocation W31370168341 @default.
• W3137016834 hasLocation W31370168342 @default.
• W3137016834 hasLocation W31370168343 @default.
• W3137016834 hasLocation W31370168344 @default.
• W3137016834 hasLocation W31370168345 @default.
• W3137016834 hasOpenAccess W3137016834 @default.
• W3137016834 hasPrimaryLocation W31370168341 @default.
• W3137016834 hasRelatedWork W2034889564 @default.

• next